DXA023-G017 / Hangzhou DAC Biotech - LARVOL DELTA

DXA023-G017, a bispecific PD-1/VEGF conjugate elicits potent anti-tumor efficacy in preclinical studies (AACR 2025) - "Although Ivonescimab, a PD-1/VEGF bispecific antibody, has exhibited a notable prolongation of progression-free survival (PFS) versus Keytruda in individuals with PD-L1-positive NSCLC, the impact on overall survival (OS) necessitates further validation. DXA023-G017, a dual-blocking anti-PD-1/VEGF bispecific conjugate, demonstrates impressive antitumor efficacy in a mouse tumor model, providing robust support for its clinical development as a treatment for various advanced solid tumors."

IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-1